Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer.

摘要: Aim The prognostic significance of KRAS, NRAS, PIK3CA and BRAF mutations was evaluated in Chinese patients with metastatic colorectal cancer (CRC). Method Tumor samples from 183 were retrospectively tested for mutations. Multivariate analysis performed to determine the relationship between mutational status, drug response survival. Result Over 70% received two or more lines chemotherapy, 50% had cetuximab 18% bevacizumab. The prevalence 45, 3.2, 5 20%, respectively. For entire cohort, median overall survival 24 months (95% confidence interval [CI] = 20.4–26.4 months). Of genes tested, only KRAS mutation an independent factor a multivariate hazard ratio 1.5 CI = 1.05–2.16, P = 0.03). In subgroup who cetuximab-based therapy first-line setting, associated lack chemotherapy (28% vs 66%, chi-square, P = 0.01). Patients mutant tumors (or wild-type that harbored and/or mutations) tended have lower rates (P = not significant). number NRAS cases too small allow any statistical analysis. Conclusion The this cohort is consistent reports non-Asian populations, has both predictive CRC.